Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Genetic modification of hypertension by sGCα1.

Sips PY, Buys ES.

Trends Cardiovasc Med. 2013 Nov;23(8):312-8. doi: 10.1016/j.tcm.2013.05.001. Review.

2.

Gender-specific hypertension and responsiveness to nitric oxide in sGCalpha1 knockout mice.

Buys ES, Sips P, Vermeersch P, Raher MJ, Rogge E, Ichinose F, Dewerchin M, Bloch KD, Janssens S, Brouckaert P.

Cardiovasc Res. 2008 Jul 1;79(1):179-86. doi: 10.1093/cvr/cvn068.

3.

Soluble guanylate cyclase-alpha1 deficiency selectively inhibits the pulmonary vasodilator response to nitric oxide and increases the pulmonary vascular remodeling response to chronic hypoxia.

Vermeersch P, Buys E, Pokreisz P, Marsboom G, Ichinose F, Sips P, Pellens M, Gillijns H, Swinnen M, Graveline A, Collen D, Dewerchin M, Brouckaert P, Bloch KD, Janssens S.

Circulation. 2007 Aug 21;116(8):936-43.

4.

Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease.

Boerrigter G, Burnett JC Jr.

Cardiovasc Drug Rev. 2007 Spring;25(1):30-45. Review.

PMID:
17445086
5.

Impaired iNOS-sGC-cGMP signalling contributes to chronic hypoxic and hypercapnic pulmonary hypertension in rat.

Xia XD, Xu ZJ, Hu XG, Wu CY, Dai YR, Yang L.

Cell Biochem Funct. 2012 Jun;30(4):279-85. doi: 10.1002/cbf.2796.

PMID:
22290599
6.

New insights into the role of soluble guanylate cyclase in blood pressure regulation.

Buys E, Sips P.

Curr Opin Nephrol Hypertens. 2014 Mar;23(2):135-42. doi: 10.1097/01.mnh.0000441048.91041.3a. Review.

7.

Notch activation augments nitric oxide/soluble guanylyl cyclase signaling in immortalized ovarian surface epithelial cells and ovarian cancer cells.

El-Sehemy A, Chang AC, Azad AK, Gupta N, Xu Z, Steed H, Karsan A, Fu Y.

Cell Signal. 2013 Dec;25(12):2780-7. doi: 10.1016/j.cellsig.2013.09.008.

PMID:
24041655
8.

Soluble guanylyl cyclase is a target of angiotensin II-induced nitrosative stress in a hypertensive rat model.

Crassous PA, Couloubaly S, Huang C, Zhou Z, Baskaran P, Kim DD, Papapetropoulos A, Fioramonti X, Durán WN, Beuve A.

Am J Physiol Heart Circ Physiol. 2012 Sep 1;303(5):H597-604. doi: 10.1152/ajpheart.00138.2012.

9.

Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis.

Wang Y, Krämer S, Loof T, Martini S, Kron S, Kawachi H, Shimizu F, Neumayer HH, Peters H.

Kidney Int. 2005 Jul;68(1):47-61.

10.

Genetic modifiers of hypertension in soluble guanylate cyclase α1-deficient mice.

Buys ES, Raher MJ, Kirby A, Shahid M, Baron DM, Hayton SR, Tainsh LT, Sips PY, Rauwerdink KM, Yan Q, Tainsh RE, Shakartzi HR, Stevens C, Decaluwé K, Rodrigues-Machado Mda G, Malhotra R, Van de Voorde J, Wang T, Brouckaert P, Daly MJ, Bloch KD.

J Clin Invest. 2012 Jun;122(6):2316-25. doi: 10.1172/JCI60119. Erratum in: J Clin Invest. 2012 Aug 1;122(8):3024. Mohd, Shahid [corrected to Shahid, Mohd].

11.

Smooth muscle-specific deletion of nitric oxide-sensitive guanylyl cyclase is sufficient to induce hypertension in mice.

Groneberg D, König P, Wirth A, Offermanns S, Koesling D, Friebe A.

Circulation. 2010 Jan 26;121(3):401-9. doi: 10.1161/CIRCULATIONAHA.109.890962.

12.

Molecular variants of soluble guanylyl cyclase affecting cardiovascular risk.

Wobst J, Rumpf PM, Dang TA, Segura-Puimedon M, Erdmann J, Schunkert H.

Circ J. 2015;79(3):463-9. doi: 10.1253/circj.CJ-15-0025. Review.

13.

Characterization of the human alpha1 beta1 soluble guanylyl cyclase promoter: key role for NF-kappaB(p50) and CCAAT-binding factors in regulating expression of the nitric oxide receptor.

Marro ML, Peiró C, Panayiotou CM, Baliga RS, Meurer S, Schmidt HH, Hobbs AJ.

J Biol Chem. 2008 Jul 18;283(29):20027-36. doi: 10.1074/jbc.M801223200.

14.

α1-A680T variant in GUCY1A3 as a candidate conferring protection from pulmonary hypertension among Kyrgyz highlanders.

Wilkins MR, Aldashev AA, Wharton J, Rhodes CJ, Vandrovcova J, Kasperaviciute D, Bhosle SG, Mueller M, Geschka S, Rison S, Kojonazarov B, Morrell NW, Neidhardt I, Surmeli NB, Aitman TJ, Stasch JP, Behrends S, Marletta MA.

Circ Cardiovasc Genet. 2014 Dec;7(6):920-9. doi: 10.1161/CIRCGENETICS.114.000763. Erratum in: Circ Cardiovasc Genet. 2015 Feb;8(1):244. Surmeli, Nur Basek [corrected to Surmeli, Nur Basak].

15.

Structure and regulation of soluble guanylate cyclase.

Derbyshire ER, Marletta MA.

Annu Rev Biochem. 2012;81:533-59. doi: 10.1146/annurev-biochem-050410-100030. Review.

PMID:
22404633
16.

Volume overload induces differential spatiotemporal regulation of myocardial soluble guanylyl cyclase in eccentric hypertrophy and heart failure.

Liu Y, Dillon AR, Tillson M, Makarewich C, Nguyen V, Dell'Italia L, Sabri AK, Rizzo V, Tsai EJ.

J Mol Cell Cardiol. 2013 Jul;60:72-83. doi: 10.1016/j.yjmcc.2013.03.019.

17.

Targeted genomic disruption of h-ras induces hypotension through a NO-cGMP-PKG pathway-dependent mechanism.

Chamorro-Jorganes A, Grande MT, Herranz B, Jerkic M, Griera M, Gonzalez-Nuñez M, Santos E, Rodriguez-Puyol D, Lopez-Novoa JM, Rodriguez-Puyol M.

Hypertension. 2010 Sep;56(3):484-9. doi: 10.1161/HYPERTENSIONAHA.110.152587.

18.
19.

Soluble guanylate cyclase stimulators in pulmonary hypertension.

Stasch JP, Evgenov OV.

Handb Exp Pharmacol. 2013;218:279-313. doi: 10.1007/978-3-642-38664-0_12. Review.

PMID:
24092345
20.

What is next in nitric oxide research? From cardiovascular system to cancer biology.

Bian K, Murad F.

Nitric Oxide. 2014 Dec 1;43:3-7. doi: 10.1016/j.niox.2014.08.006. Review.

PMID:
25153032
Items per page

Supplemental Content

Support Center